Jules Mitchel of Target Health discusses risk-based monitoring trends in the clinical trials industry
Jules Mitchel of Target Health discusses What is different now about risk-based monitoring vs. what companies may have been doing more innovatively about monitoring in the past in the clinical trials industry.
- Increasing Intensity of On-Site Monitoring a Troubling Trend
- Industry Metric Indicates Low ROI with Full Source Document Verification
- Has FDA Guidance on Risk-based Monitoring Impacted SDV Coverage Yet?More in Risk-Based Monitoring